Amicus Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Amicus Therapeutics has a total shareholder equity of $160.2M and total debt of $387.9M, which brings its debt-to-equity ratio to 242.1%. Its total assets and total liabilities are $777.9M and $617.7M respectively.
Key information
242.1%
Debt to equity ratio
US$387.86m
Debt
Interest coverage ratio | n/a |
Cash | US$286.20m |
Equity | US$160.17m |
Total liabilities | US$617.71m |
Total assets | US$777.88m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AM6's short term assets ($483.1M) exceed its short term liabilities ($167.7M).
Long Term Liabilities: AM6's short term assets ($483.1M) exceed its long term liabilities ($450.0M).
Debt to Equity History and Analysis
Debt Level: AM6's net debt to equity ratio (63.5%) is considered high.
Reducing Debt: AM6's debt to equity ratio has increased from 93.8% to 242.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AM6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AM6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.